1 / 6

Executive Summary

Executive Summary. Platform Technology (TSCP): Fusion proteins with two functional ends First-in-class drugs to convert inter-cellular signals Studied for a decade / Multiple scientific publications Wide IP estate licensed from the University of Pennsylvania Products

rance
Télécharger la présentation

Executive Summary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Executive Summary • Platform Technology (TSCP): • Fusion proteins with two functional ends • First-in-class drugs to convert inter-cellular signals • Studied for a decade / Multiple scientific publications • Wide IP estate licensed from the University of Pennsylvania • Products • Pipeline: Four TSCP fusion combinations • Two products in pre-clinical development • Autoimmune indications with unmet needs • KAHR-101 • Complete production process developed • Efficacy demonstrated in multiple animal disease models • Clinical trials expected in 2010 in RA patients

  2. Company Information • Hadasit Bio-Holdings (“HBL”, TASE: HDST) portfolio company • Located in Israel • Operations initiated mid 2007 • Platform technology; ‘Trans signal converter proteins (TSCP)’. Licensed from the University of Pennsylvania • Leading products: KAHR-101 & KAHR-102 for the treatment of autoimmune diseases

  3. Team • CEO – Dr. Noam Shani, Ph.D. Previous VP-R&D for Medgenics (AIM: MEDG) and for Compugen (NASDAQ: CGEN) • Research Officer- Dr. Michal Dranitzki Elhalel, M.D. Senior physician and scientist at the Hadassah Medical Center. Investigating the TSCP technology since 2000 • Scientific Advisory Board • Prof. Marc Feldmann, M.D., Ph.D. Head, Kennedy Institute of Rheumatology - Imperial College, London. Developed Ramicade (J&J) • Prof. Lawrence Steinman, M.D. Chair of Immunology at Stanford University. Developed Tysabri (Biogen-Idec) • Dr. Nabil Hanna, Ph.D. Previous Executive Vice President Research, Biogen-Idec. Developed Rituximab and Zevalin (Biogen-Idec) • Prof. Mark Tykocinski, M.D. Dean, Jefferson Medical College, Philadelphia. Inventor of the TSCP platform technology

  4. Platform Technology: TSCP • Represents the third generation of protein-based therapeutics • First generation: Protein with one functional unit and one target (e.g. IFN, EPO, hGH) • Second generation: Protein with twofunctional units and one target (e.g. mAb, Fc-fusions) • Third generation: Protein with twofunctional units and two targets (TSCP molecules) • Fusion proteins with Two functional ends • Both sides transmit different and complementary intercellular or intracellular signals • Intensely studied for a decade, mostly by U. Penn and Hadassah teams • Drug potential documented in multiple scientific publications * • IP was licensed from U. Penn * See website for scientific publications – www.kahr-medical.com

  5. KAHR-101/102 Three-Year Plan

  6. KAHR Opportunity • Technological breakthrough – TSCP platform technology • Huge market with unmet clinical needs • Competitive advantage over existing paradigm • Robust development pipeline • Strong IP portfolio • Seasoned team • KAHR has initiated a series-A financing round and is seeking strategic investments, licensing and co-development collaborations

More Related